Awesome Find Riz. Sweet Article. As this exper

Awesome Find Riz. Sweet Article.

As this expert explains, leronlimab is part of the group of drugs called CCR5 co-receptor inhibitors or antagonists, one of the locks that HIV must open to infect CD4 T lymphocytes —the immune cells that are its priority target—, but which is also implicated in other pathologies, such as multiple sclerosis, covid-19 or metastatic cancer.

Thus, among the other potential therapeutic applications of leronlimab is a type of breast cancer that also has CCR5 and the prevention of graft-versus-host disease, a serious complication of bone marrow transplants.

Monoclonal antibodies (or mABs ), such as leronlimab, are man-made proteins produced by B lymphocytes that act like human antibodies: binding to a specific protein (antigen) that the immune system or researchers want to neutralize. They are already used to treat diseases such as various types of cancer or even severe covid-19 and have been tested as an alternative chronic therapy to ART in certain people with HIV .

The leronlimab target antigen is CCR5, a protein present on the surface of human cells, such as CD4 T lymphocytes. As Santiago Moreno Guillén, head of the Infectious Diseases service at the Ramón y Cajal University Hospital, explained to SINC, HIV identifies the CD4 receptor present on its surface that gives it its name and uses it as the main lock to access them. But to achieve this, you need to open a second lock or co-receptor, which in most people is the CCR5.

so much more in the article